Results 131 to 140 of about 1,571,779 (177)

Kinetic Behavior of ‘Pathological’ Myeloblasts and ‘Normal’ Erythroblasts in Acute Granulocytic Leukemia

Oncology, 2009
Kinetic studies of leukemic blast cells (LBC) and erythroblasts were carried out in 20 cases of acute myeloblasts leukemia (AML), and the results were compared with those observed in dividing granulocytic precursors (DGP) and erythroblasts in a control group of 16 normal subjects.
J. Sánchez-Fayos, J. Outeiriño, J.M. Fernández-Rañada, M.T. Calabuig   +3 more
openaire   +1 more source

Erythroblast predominance without CD41/cyCD41-positive blasts predicts favorable prognosis in patients with myelodysplastic syndromes and acute myeloid leukemias treated with azacitidine

International Journal of Hematology, 2022
This study examined the prognostic impact of erythroblast predominance (EP) in 61 patients with myelodysplastic syndromes (MDS) (n = 51) or acute myeloid leukemia (n = 10) treated with azacitidine. Median age was 78 years. EP, defined as > 40% erythroblasts and M/E 
Akihito Matsuoka, Masaki Tanibuchi, Ieharu Yamazaki, Teruhisa Taoka   +3 more
openaire   +2 more sources

Distinctive Multidrug Sensitivity and Outcome of Acute Erythroblastic and Megakaryoblastic Leukemia in Children With Down Syndrome

International Journal of Hematology, 2001
We assessed the in vitro chemosensitivity of acute erythroblastic and megakaryoblastic leukemia cells from children with Down syndrome (DS) compared to non-DS children. We conducted in vitro tests using the MTT assay of bone marrow samples from 12 children with DS and 16 children without DS.
S, Yamada, T, Hongo, S, Okada, C, Watanabe, Y, Fujii, H, Hori, M, Yazaki, R, Hanada, Y, Horikoshi   +8 more
openaire   +2 more sources

Derivative (1;7)(q10;p10) in a Patient with de novo Acute Erythroblastic Leukemia (AML-M6)

Cancer Genetics and Cytogenetics, 1999
A rare association of der(1;7)(q10;p10) with de novo acute erythroblastic leukemia (AML-M6) in a 63-year-old male is reported. While this unbalanced 1;7 translocation, der(1;7), has been reported often in therapy-related myelodysplastic syndrome (t-MDS) or therapy-related acute myeloid leukemia (t-AML), its associations with de novo AML-FAB-M6 have ...
N, Obara, A, Shinagawa, T, Komatsu, T, Abe, H, Ninomiya   +4 more
openaire   +2 more sources

Micronuclei and Nuclear Abnormalities Observed in Erythroblasts in Myelodysplastic Syndromes and in de novo Acute Leukemia after Treatment

Acta Haematologica, 1999
The frequencies of erythroblasts with micronuclei (EBM) and erythroblasts with aberrant nuclear shapes (EBAN) in bone marrow were evaluated in 60 patients with untreated myelodysplastic syndrome (MDS), and also in 21 patients with acute leukemia before and after treatment, and the results were compared regarding cytogenetic patterns.
H, Yashige, S, Horiike, M, Taniwaki, S, Misawa, T, Abe   +4 more
openaire   +2 more sources

A case of 8p11 syndrome associated with acute erythroblastic leukemia and T-lymphoblastic lymphoma treated with ponatinib combination and chemotherapy

Hématologie, 2017
Le syndrome 8p11 est un syndrome rare dont le pronostic defavorable est du a une progression rapide vers une leucemie aigue myeloide (LAM) ou vers un lymphome lymphoblastique. Il resulte d’une mutation acquise impliquant le gene FGFR1 situe en p11 sur le chromosome 8 (translocation ou insertion chromosomiques).
Cécile Torregrosa, Jeanne Chen, Pauline Vaflard, Diane Lara, Solène Houlle-Crépin, Isabel Garcia, Christine Terre, Julien Moroch, Philippe Rousselot, Juliette Lambert   +9 more
openaire   +1 more source

The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50%

Leukemia Research, 2017
We reviewed the cases of 68 consecutive patients who were diagnosed with myelodysplastic syndrome (MDS, n=61) or acute erythroleukemia (AEL, n=7) according to the World Health Organization (WHO) 2008 criteria and had previously been treated with azacitidine, a hypomethylating agent. Fifteen MDS patients had bone marrow erythroblast frequencies of ≥50%,
Tomoyuki, Uchida, Masao, Hagihara, Jian, Hua, Morihiro, Inoue   +3 more
openaire   +2 more sources

[Acute basophilic leukemia with an intense erythroblastic reaction].

Sangre, 1994
A patient is presented who had acute basophilic leukaemia with intense erythroblastic reaction. The patient, a 66 year-old man, complained of general malaise, increased abdominal perimeter and melena. Leucocytosis, as well as severe anaemia and thrombocytopenia, were found in his peripheral blood.
M, Batlle, J M, Ribera, O, García-Vidal, J, Roncalés, F, Millá, E, Feliu   +5 more
openaire   +1 more source

Unusually Long Survival of a 67-Year-Old Patient with Near-Tetraploid Acute Myeloid Leukemia M0 without Erythroblastic and Megakaryocytic Dysplasia

Acta Haematologica, 2011
Patients with near-tetraploid acute myeloid leukemia (NT-AML) typically have poor survival. We present the case of a 67-year-old Caucasian male with NT-AML M0 who had an unusually long first complete remission of 51 months and an overall survival of 80 months.
Petr, Lemež, Hana, Klamová, Zuzana, Zemanová, Iuri, Marinov, Ota, Fuchs, Jiří, Schwarz, Jana, Březinová, Dana, Provazníková, Arnošt, Kostečka, Jana, Marková, Kyra, Michalová, Jaroslav, Jelínek   +11 more
openaire   +2 more sources

Erythroblastic and/or megakaryocytic dysplasia in de novo acute myeloid leukemias M0–M5 show relation to myelodysplastic syndromes and delimit two main categories

Leukemia Research, 2000
Erythroblastic and/or megakaryocytic dysplasia (EMD) was evaluated in diagnostic bone marrow smears of 43 consecutively treated patients under 65 years with de novo acute myeloid leukemia (AML) M0-M5 according to FAB criteria. The evaluation was possible in 39 (91%) patients, i.e.
P, Lemez, J, Gáliková, T, Haas
openaire   +2 more sources